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Résumé en
anglais
The retest effect-improvement of performance on second exposure to a task-may
impede the detection of cognitive decline in clinical trials for neurodegenerative
diseases. We assessed the impact of the retest effect in Huntington's disease trials,
and investigated its possible neutralization. We enrolled 54 patients in the
Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD) trial and 39 in
the placebo arm of the Riluzole trial in Huntington's Disease (RIL-HD). All were
assessed with the Unified Huntington's Disease Rating Scale (UHDRS) plus
additional cognitive tasks at baseline (A1), shortly after baseline (A2) and one year
later (A3). We used paired t-tests to analyze the retest effect between A1 and A2. For
each task of the MIG-HD study, we used a stepwise algorithm to design models
predictive of patient performance at A3, which we applied to the RIL-HD trial for
external validation. We observed a retest effect in most cognitive tasks. A decline in
performance at one year was detected in 3 of the 15 cognitive tasks with A1 as the
baseline, and 9 of the 15 cognitive tasks with A2 as the baseline. We also included
the retest effect in performance modeling and showed that it facilitated performance
prediction one year later for 14 of the 15 cognitive tasks. The retest effect may mask
cognitive decline in patients with neurodegenerative diseases. The dual baseline can
improve clinical trial design, and better prediction should homogenize patient
groups, resulting in smaller numbers of participants being required.
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